Literature DB >> 8241613

Drug-induced autoimmune hemolytic anemia.

L D Petz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8241613     DOI： 10.1016/s0887-7963(93)70144-3

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN： 0887-7963


× No keyword cloud information.
  8 in total

1.  Comparison of conventional tube test technique and gel microcolumn assay for direct antiglobulin test: a large study.

Authors:  M C Z Novaretti; E Jens; T Pagliarini; S L Bonifacio; P E Dorlhiac-Llacer; D A F Chamone
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Use of gel microcolumn assay for the detection of drug-induced positive direct antiglobulin tests.

Authors:  M C Z Novaretti; C R Sopeleti; P E Dorlhiac-Llacer; D A F Chamone
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

3.  RIFAMPICIN INDUCED PLATELET DYSFUNCTION.

Authors:  S J Varghese; A K Rajput; K E Rajan
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Immune-mediated severe hemolytic crisis with a hemoglobin level of 1.6 g/dl caused by anti-piperacillin antibodies in a patient with cystic fibrosis.

Authors:  S Kunzmann; W Thomas; B Mayer; S Kuhn; H Hebestreit
Journal:  Infection       Date:  2010-03-05       Impact factor: 3.553

5.  Beta-lactam-induced severe neutropenia: a descriptive study.

Authors:  Richard H Aster
Journal:  Fundam Clin Pharmacol       Date:  2019-04       Impact factor: 2.748

Review 6.  Autoimmune hemolytic anemia.

Authors:  C Hashimoto
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

7.  Ceftriaxone-related hemolysis and acute renal failure.

Authors:  Erkan Demirkaya; Abdullah Avni Atay; Ugur Musabak; Ali Sengul; Faysal Gok
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

Review 8.  Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance.

Authors:  W N Patton; S B Duffull
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.